[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1992

Inocoterone and AcneThe Effect of a Topical Antiandrogen: Results of a Multicenter Clinical Trial

Author Affiliations

From the Division of Dermatology (Dr Lookingbill) and the Center for Biostatistics and Epidemiology (Dr Landis), and the Department of Medicine, Pennsylvania State University College of Medicine, Hershey; Hoechst-Roussel Pharmaceuticals Inc, Somerville, NJ (Drs Abrams and Ramaswamy and Mr Cherill); Department of Dermatology, University of Michigan Medical Center, Ann Arbor (Drs Ellis and Ortiz-Ferrer); Department of Dermatology, University of Pittsburgh (Pa) (Dr Jegasothy); Dermatology Research Associates, Cincinnati, Ohio (Dr Lucky); Department of Dermatology, Yale School of Medicine, New Haven, Conn (Dr Savin); Department of Dermatology, New York (NY) University Medical Center (Drs Shupack and Stiller); Division of Dermatology, University of Utah Medical School, Salt Lake City (Dr Zone); and Department of Dermatology, Boston (Mass) University School of Medicine (Dr Pochi).

Arch Dermatol. 1992;128(9):1197-1200. doi:10.1001/archderm.1992.01680190053005
Abstract

• Background and Methods.—  Because acne is androgen dependent, antiandrogen therapy might improve the condition. Inocoterone acetate (RU 882) is a nonsteroidal antiandrogen that binds to the androgen receptor and has antiandrogenic activity in animal models. To test its topical effect on acne, 126 male subjects with facial acne completed a 16-week, multicenter, double-blind study in which the twicedaily application of a 10% solution of inocoterone was compared with vehicle solution. Baseline and monthly examinations included acne lesion counts and general and endocrine laboratory tests.

Results.—  Inflammatory papules and pustules showed greater reduction in the inocoterone-treated subjects than in the subjects treated with vehicle. This difference achieved statistical significance by week 12 (24% reduction vs 10%) and week 16 (26% reduction vs 13%) and, with longitudinal analysis, throughout the course of the study. Global assessments and changes in comedo counts and sebum excretion rates were not significantly different between the groups. No serious adverse reactions were encountered.

Conclusions.—  In this double-blind study of 126 male subjects with acne, a topical solution of the antiandrogen inocoterone, compared with vehicle, produced a modest but statistically significant reduction in the number of inflammatory acne lesions.(Arch Dermatol. 1992;128:1197-1200)

×